3 not yet recruiting, 3 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Not yet recruiting 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Luminary Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies LMY-922 - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | Luminary Therapeutics | 27 | 2026-09-01 | 2026-07-01 |
| BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus LMY-920 - Systemic Lupus Erythematosus | Phase 1 | Recruiting | Luminary Therapeutics | 18 | 2025-04-01 | 2025-06-03 |
| LMY-920 for Treatment of Relapsed or Refractory Myeloma Autologous CAR-T cell therapy expressing the BAFF-ligand. - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Luminary Therapeutics | 30 | 2024-03-13 | 2024-10-18 |
| Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma BAFF CAR-T - Lymphoma, Non-Hodgkin Lymphoma, B-Cell | Phase 1 | Recruiting | Luminary Therapeutics | 20 | 2023-11-21 | 2024-10-21 |
Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Lymphoma (2) · Lymphoma, B-Cell (2) · Arthritis, Rheumatoid (1) · Dermatomyositis (1) · Leukemia, Hairy Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Neoplasms (1) · Recurrence (1) · Scleroderma, Systemic (1)
United States (5)
Dean Lee, PhD (1) · Leland Metheny, MD (1) · Paolo F. Caimi, MD (1)